<DOC>
	<DOCNO>NCT00837759</DOCNO>
	<brief_summary>Background : - Type 1 diabetes ( T1D ) occur immune system attack insulin-producing cell ( beta cell ) pancreas , result death . - Insulin injection currently best method control blood sugar individual T1D . However , animal study show drug sitagliptin lansoprazole help reverse beta cell damage develop new beta cell . In addition , Diamyd show weaken immune process attack pancreatic beta cell . Objectives : - To find whether combination treatment sitagliptin , lansoprazole , Diamyd help maintain functioning beta cell and/or cause new beta cell form . - To determine drug combination affect insulin dos blood sugar control . - To determine whether drug combination affect immune response involve T1D .</brief_summary>
	<brief_title>Novel Therapy Preserve Beta Cell Function New Onset Type 1 Diabetes</brief_title>
	<detailed_description>Type 1 diabetes ( T1D ) end result immune mediate beta-cell destruction . It generally accept time T1D diagnose , individual lose ( 60-80 % ) his/her beta cell function . The loss insulin-producing beta cell believe occur period month year individual retain endogenous insulin production even year clinical diagnosis diabetes . The presence residual beta cell mass may signify complex interplay auto-destructive immune response capacity limit beta cell regeneration . When initiated T1D onset , immunosuppression show preserve beta cell function , significant limit toxicity . Selectively target pathogenic T-cells involve T1D development progression could achieve objective less toxicity . Various study non-obese diabetic ( NOD ) mouse model spontaneous autoimmune diabetes demonstrate administer glutamic acid decarboxylase ( GAD65 ) , beta cell autoantigen , prevent immune destruction delay prevent diabetes onset . Preclinical study also identify several growth factor , include epidermal growth factor ( EGF ) , glucagon-like peptide 1 ( GLP-1 ) , gastrin , appear promote beta cell proliferation . We seek test potential preserving beta cell function early disease course T1D combine antigen-specific immunomodulation regenerative stimulus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Recently diagnose ( within precede 4 month screen ) diabetes clinically consistent T1D : A . Positive antiGAD antibody . B. BMI 19 28 kg/m2 ; age 16 18 , BMI must within 10th 90th percentile age . 2 . Ages 16 30 year , inclusive 3 . Random plasma Cpeptide level equal great 0.20 nmol/L 4 . Willingness ability institute intensive insulinbased glucose management . EXCLUSION CRITERIA : 1 . Diabetic nephropathy creatinine clearance le 60 cc/min 24 hour urine albumin great 300 mg 2 . Insulin requirement great 0.8 units/kg/day end runin period 3 . Regular use proton pump inhibitor within 3 month enrollment 4 . Use GLP1R agonist DPP4 inhibitor within 6 month prior enrollment 5 . Use immunosuppressive therapy precede 12 month 6 . Evidence chronic infection , example , know human immunodeficiency virus ( HIV ) hepatitis 7 . History malignancy treat basal squamous skin cancer 8 . Any chronic medical condition unduly increase risk potential enrollee judge study investigator 9 . Pregnancy , breastfeed plan pregnancy within two year , woman reproductive age use effective mode contraception unwilling continue adequate contraception 1 year last study drug administration 10 . Any coexisting condition/circumstances would make patient unsuitable participate study , deem investigator . For example , study investigator would exclude potential candidate following ( list inclusive ) : A. Clinically significant past history acute reaction vaccine drug B . Recent participation clinical trial new chemical entity C. A history alcohol drug abuse D. Significant neurological condition like epilepsy , head trauma , cerebrovascular accident E. Individuals significant gastrointestinal disorder determine study investigator influence either study safety data interpretation . Such condition include limited gastroparesis gastric bypass surgery F. Individuals condition prone hypergastrinemia ( ZollingerEllison syndrome , use histamine2 receptor blocker ) hypogastrinemia ( gastric surgery ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Type I Diabetes</keyword>
	<keyword>Preserve Beta Cell Function</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Lansoprazole</keyword>
	<keyword>GAD65 ( Diamyd )</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>T1DM</keyword>
</DOC>